New Niagen® Nicotinamide Riboside (NR) Study Deepens Understanding of NAD Decline and Hearing Loss in Animal Model
February 27 2020 - 6:30AM
ChromaDex Corp. (NASDAQ:CDXC), a global scientific authority on
nicotinamide adenine dinucleotide (NAD) and nicotinamide riboside
(NR) science, announced today the publication of a preclinical
study in the journal Aging and Mechanisms of Disease, part of
Nature Partner Journals. Conducted by the National Institute
on Aging and the National Institute on Deafness and Other
Communication Disorders, components of the National Institutes of
Health, and the University of Copenhagen, the study demonstrated a
reduction of hearing loss from Niagen® supplementation in mice.
“These findings are potentially meaningful for those with
Cockayne syndrome as well as the broader aging population who
experience hearing loss,” commented Dr. Vilhelm A. Bohr, Senior
Investigator, NIH National Institute on Aging, and study principal
investigator. “The next step is to move this animal model
research into a human trial.”
Further investigation into this research is important given that
approximately one in three people between the ages of 65 and 74
experiences hearing loss and nearly half of those older than 75
have difficulty hearing. The hearing loss experienced by Cockayne
syndrome patients is similar to the sensorineural age-related
hearing loss (ARHL) commonly found in older adults. Currently,
there is a great need for additional interventions given the only
remedies include assistive devices such as hearing aids, and no
preventative measures are available.
As documented in previously published preclinical research,
nicotinamide adenine dinucleotide (NAD) depletion plays an
important role in the cause of ARHL, and these latest preclinical
trial results suggest NR, a proven NAD booster, may exert a
dose-dependent reduction in hearing loss by aiding auditory
interpretation and neurotransmission of sounds to the brain. These
results reinforce findings from earlier preclinicals which
suggested NR may help in delaying or reducing age-related hearing
loss (ARHL), though further studies are required to confirm these
findings in humans.
ChromaDex supplied its novel ingredient, Niagen® (nicotinamide
riboside), as research material for the independent study. “We
appreciate this deeper knowledge into the relationship between NAD
decline and hearing loss,” says Dr. Andrew Shao, ChromaDex Senior
Vice President of Global Scientific & Regulatory Affairs. “The
findings highlight an important emerging area of research for NR
which we hope to explore in human subjects.”
For additional information on the science supporting NR and
Niagen, please visit www.chromadex.com.
About ChromaDex:ChromaDex Corp. is a
science-based integrated nutraceutical company devoted to improving
the way people age. ChromaDex scientists partner with leading
universities and research institutions worldwide to uncover the
full potential of NAD and identify and develop novel, science-based
ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside
chloride, sold directly to consumers as TRU NIAGEN®, is backed with
clinical and scientific research, as well as extensive IP
protection. TRU NIAGEN® is helping the world AGE BETTER®. ChromaDex
maintains a website at www.chromadex.com to which ChromaDex
regularly posts copies of its press releases as well as additional
and financial information about the Company.
Forward-Looking Statements:This release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities and Exchange Act of 1934, as amended, including
statements related to NR and whether the findings are meaningful
for those with Cockayne syndrome as well as the broader aging
population who experience hearing loss. Statements that are not a
description of historical facts constitute forward-looking
statements and may often, but not always, be identified by the use
of such words as "expects", "anticipates", "intends", "estimates",
"plans", "potential", "possible", "probable", "believes", "seeks",
"may", "will", "should", "could" or the negative of such terms or
other similar expressions. More detailed information about
ChromaDex and the risk factors that may affect the realization of
forward-looking statements is set forth in ChromaDex's Annual
Report on Form 10-K for the fiscal year ended December 31, 2018,
ChromaDex's Quarterly Reports on Form 10-Q and other filings
submitted by ChromaDex to the SEC, copies of which may be obtained
from the SEC's website at www.sec.gov. Readers are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date hereof, and actual results may differ
materially from those suggested by these forward-looking
statements. All forward-looking statements are qualified in their
entirety by this cautionary statement and ChromaDex undertakes no
obligation to revise or update this release to reflect events or
circumstances after the date hereof.
ChromaDex Media Contact:Alex Worsham, Senior
Director of Global Corporate Communications310-388-6706 ext.
689alexw@chromadex.com
ChromaDex Investor Relations Contact:Brianna
Gerber, Vice President of FP&A and Investor
Relations949-419-0288 ext. 127briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Jul 2024 to Aug 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Aug 2023 to Aug 2024